GGrantIndex
Sort

261,768 grants matching gene therapy

NADPH Oxidases as Novel Targets for Cancer Therapy

$1,024,528
James Doroshow · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Retroviral genetic modification of PBLs to optimize expansion for cell therapy

$1,024,494
Nicholas Klemen · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

The MYC Transcription Factor Network and the Path to Cancer

$1,024,317
Robert Neil Eisenman · Fred Hutchinson Cancer Research Center · R35 · FY2019 · CA

Virological Measurements of Cryptic Replication

$1,024,059
Mario Stevenson · University Of Minnesota · P01 · FY2009 · AI

SBIR Phase II: High-Throughput Specific Cell Loading by Optoinjection

$1,024,000
Glenn Sasaki · Cyntellect, Inc · · FY2003 · TIP

Non-cytotoxic augmentation of fetal hemoglobin and bone marrow reserves

$1,023,811
Yogen Saunthararajah · University Of Michigan At Ann Arbor · P01 · FY2022 · HL

Cytoplasmic mislocalization of p27Kip1 as a causative factor and prognostic marke

$1,023,777
Peggy L Porter · Fred Hutchinson Cancer Research Center · P50 · FY2010 · CA

Inhibition of Malaria Chloroquine Resistance Transporters

$1,023,775
M.g. Finn · Scripps Research Institute, The · R56 · FY2010 · AI

Late Effects of Treatment in Wilms Tumor Survivors and Offspring

$1,023,737
Norman E Breslow · Fred Hutchinson Cancer Research Center · R01 · FY2009 · CA

Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease

$1,023,733
Jin Wang · Baylor College Of Medicine · U01 · FY2023 · AG

Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery

$1,023,709
Matthew L Meyerson · Dana-Farber Cancer Inst · R35 · FY2023 · CA

Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery

$1,023,709
Matthew L Meyerson · Dana-Farber Cancer Inst · R35 · FY2022 · CA

Molecular and Cellular Mechanisms of Experience-Dependent Cortical Processing

$1,023,668
Kuan Wang · National Institute Of Mental Health · ZIA · FY2009 · MH

Immunotherapy of low grade lymphoid malignancies

$1,023,663
Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL

Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies

$1,023,609
Nirali Shah · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

Decoding epigenetic scars of smoldering neuroinflammation and CNS complications in people with HIV

$1,023,588
Michael Jay Corley · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · MH

BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas

$1,023,555
James D Crapo · Biomimetix Jv, Llc · R44 · FY2016 · CA

Studies of the Natural History of Sickle Cell Disease

$1,023,525
Swee Lay Thein · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL

Program Project Grant

$1,023,474
Thomas Jefferson University · P01 · FY2005 · AR

Molecular Biology Of Outer Retina-specific Proteins

$1,023,337
Thomas Redmond · National Eye Institute · ZIA · FY2016 · EY

GLIOMAS--BIOLOGIC, MOLECULAR AND GENETIC STUDIES

$1,023,265
University Of Texas Md Anderson Can Ctr · P01 · FY2000 · CA

First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development

$1,023,231
Rajesh Krishnan · Oncternal Therapeutics, Inc. · R44 · FY2022 · CA

Non-cytotoxic augmentation of fetal hemoglobin and bone marrow reserves

$1,023,118
Yogen Saunthararajah · University Of Michigan At Ann Arbor · P01 · FY2023 · HL

The Northwestern University Cancer Health Equity Research SPORE (NU-CHERS)

$1,023,100
Melissa A. Simon · Northwestern University At Chicago · P20 · FY2021 · CA

Systems Biology Approaches to Viral Pathogenesis and Immunity

$1,023,092
Michael G Katze · Oregon Health & Science University · U54 · FY2010 · AI